Safety and Tolerability of Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy for IgA Nephropathy

Kidney360. 2024 Nov 1;5(11):1692-1705. doi: 10.34067/KID.0000000000000563. Epub 2024 Aug 26.

Authors

Akihito Tanaka¹, Kazuhiro Furuhashi¹, Kumiko Fujieda¹, Asuka Horinouchi², Kayaho Maeda², Shoji Saito¹, Tetsushi Mimura³, Yosuke Saka³, Tomohiko Naruse³, Takuji Ishimoto⁴, Noritoshi Kato², Tomoki Kosugi², Fumie Kinoshita⁵, Yachiyo Kuwatsuka⁵, Yasuhiro Nakai⁵, Shoichi Maruyama²

Affiliations

¹ Department of Nephrology, Nagoya University Hospital, Nagoya, Japan.
² Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
³ Department of Nephrology, Kasugai Municipal Hospital, Kasugai, Japan.
⁴ Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
⁵ Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

PMID: 39186380
DOI: 10.34067/KID.0000000000000563

No abstract available

Associated data

ClinicalTrials.gov/NCT04342325

Grants and funding